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Test sensitivity of mammography and mean
sojourn time over 40 years of breast cancer
screening in Nijmegen (The Netherlands)
AMWM Aarts1, SW Duffy2, SME Geurts3, DP Vulkan2, JDM Otten1,
C-Y Hsu4, THH Chen4, ALM Verbeek1 and MJM Broeders1,5
Abstract
Objectives: We investigated whether changes in mammographic technique and screening policy have improved mammo-
graphic sensitivity, and elongated the mean sojourn time, since the introduction of biennial breast cancer screening in Nijmegen,
the Netherlands, in 1975.
Methods: Maximum likelihood estimation, non-linear regression, and Markov Chain Monte Carlo simulation were used to
estimate test sensitivity, mean sojourn time, and underlying breast cancer incidence in four time periods, covering 40 years of
breast cancer screening in Nijmegen (1975–2012).
Results: Maximum likelihood estimation generated an estimated test sensitivity of approximately 90% and a mean sojourn time
around three years, while the estimates based on non-linear regression and Markov Chain Monte Carlo simulation were 80%
and four years, respectively. All three methods estimated a rise in the underlying breast cancer incidence over time, with
approximately one case more per 1000 women per year in the final period compared with the first period.
Conclusions: The three methods showed a slightly higher mammographic sensitivity and a longer mean sojourn time in the
last period, after the introduction of digital mammography. Estimates were more realistic for the more sophisticated methods,
non-linear regression and Markov Chain Monte Carlo simulation, while the simple closed form approximation of maximum
likelihood estimation led to rather high estimates for sensitivity in the early periods.
Keywords
Breast cancer screening, mammography, sojourn time, test sensitivity
Date received: 4 July 2018; accepted: 1 November 2018
Introduction
Analyses of the national breast cancer screening program
in the Netherlands have shown that breast cancer can be
detected early and that breast cancer mortality has
decreased since the introduction of screening, while esti-
mates of overdiagnosis are considered acceptable.1 The
start of the Dutch breast cancer screening program in
1989 was preceded by pilot studies in Utrecht and
Nijmegen.2,3 Since the introduction of biennial breast
cancer screening in Nijmegen in 1975, the mammographic
technique has improved, and has recently changed from
analogue to digital. The hypothesis is that these techno-
logical advances, as well as other changes within the pro-
gram (e.g. to increase the referral rate) led to an improved
test sensitivity of mammography, and an elongation of the
mean sojourn time. Sojourn time can be defined as the
duration of the preclinical screen-detectable phase, i.e.
the period during which a woman is asymptomatic but
the breast cancer is detectable by mammography.4 Test
sensitivity is the probability that a woman with asymptom-
atic breast cancer undergoing mammographic screening
during the preclinical detectable phase will have her
1Department for Health Evidence, Radboud Institute for Health Sciences,
Radboud University Medical Center, Nijmegen, The Netherlands
2Wolfson Institute of Preventive Medicine, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London, London, UK
3Department of Medical Oncology, GROW-School for Oncology and
Developmental Biology, Maastricht University Medical Center, Maastricht,
The Netherlands
4Institute of Epidemiology and Preventive Medicine, National Taiwan
University, Taipei
5Dutch Expert Centre for Screening, Nijmegen, The Netherlands
Corresponding author:
AMWM Aarts, Department for Health Evidence, Radboud Institute for
Health Sciences, Radboud University Medical Center, Geert Grooteplein Zuid
10, 6525 GA Nijmegen, The Netherlands.
Email: Anne.Aarts@Radboudumc.nl
J Med Screen
2019, Vol. 26(3) 147–153
! The Author(s) 2018
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0969141318814869
journals.sagepub.com/home/msc
breast cancer detected by the test.4 As the effectiveness of
breast cancer screening crucially depends on test sensitivity
and mean sojourn time, these measures were estimated
when the breast cancer screening program was introduced,
but the estimates have not been updated following the
technological advances in mammography and policy
changes in the program.5
The challenge of quantifying mean sojourn time is that it
is not directly observable. It can, however, be estimated.
The easiest method is to use tumour volume doubling
times as a proxy, as mean sojourn time can be seen as a
measure of tumour growth.6,7 Several methods, some
simple and some complex, have been developed for the esti-
mation of mean sojourn time based on screening frequency
data and breast cancer prevalence and incidence data,
which are easily obtainable. Methods described in the cur-
rent literature include simple methods based on the ratio of
prevalence of the disease at first screening examination
related to the expected annual incidence rate,8 parametric
models assuming a specific distribution for sojourn time,9,10
nonparametric methods with time split into discrete inter-
vals,11 simulation models with patient-level data,12 and
Markov models simulating the natural history of chronic
diseases.13 As there is no gold standard to estimate mean
sojourn time, the reliability of all these estimation methods
remains unclear. We therefore applied three different esti-
mation methods, to investigate whether they gave similar
results which can still be incorrect. As our interest was in
measuring the effect of technological advances inmammog-
raphy and changes in policy over several decades, we
wanted to obtain multiple estimates for test sensitivity
and mean sojourn time. The most relevant change is the
shift from analogue to digital mammography in 2007, and
its accompanying higher breast cancer detection rate.14
In this paper, we investigate whether technological
advances in mammography and changes in screening
policy have improved the test sensitivity of mammography
and elongated the correlated mean sojourn time. We illus-
trate this by applying three different estimation methods,
using almost 40 years of data from the Nijmegen breast
cancer screening program.
Methods
A pilot study on biennial breast cancer screening with ana-
logue mammography started in 1975 in the city of
Nijmegen, the Netherlands.15 After promising results
from this pilot, and another in Utrecht, the Dutch govern-
ment decided to implement nationwide biennial breast
cancer screening,2,3,16 and from 1989 the Nijmegen pro-
gram became part of the national program. The Dutch
government was responsible for the execution and quality
control of the program and the training of the radiologists
and radiographers. After the implementation period of the
national program, the referral rate was 10 per 1000 women
screened, with a somewhat disappointing breast cancer
detection rate. The result triggered an investigation into
the optimal referral rate in the early 2000s.17 Based on
this ‘optimization study,’ the Dutch Expert Centre for
Screening recommended an increase in the referral rate
to 20 per 1000 women screened. In 2007, the breast
cancer screening program in Nijmegen switched from ana-
logue to digital mammography.18 This further increased
the referral rate to around 25 per 1000 women screened.19
During the 40 years of breast cancer screening in
Nijmegen, women in varying age ranges were invited, but
women aged 50–69 were consistently invited. For these
women, the following data were collected: invitation for
screening, participation in screening, referral for further
diagnostic work-up, and diagnosis of a screen-detected
cancer or interval cancer (a cancer detected between two
consecutive screening rounds). These data were used to esti-
mate test sensitivity of mammography and mean sojourn
time. To investigate the effect of changes in mammographic
technique and screening policy on these two parameters, the
data of the Nijmegen breast cancer screening program
(1975–2012) were grouped in four periods: (1) pilot study
in Nijmegen (1975–1988); (2) introduction of nationwide
breast screening program (1989–2000); (3) publication of
study on increasing the Dutch referral rate (2001–2006);
and (4) introduction of digital mammography (2007–2012).
For each of these periods we obtained estimates of test sen-
sitivity, mean sojourn time, and the underlying breast
cancer incidence. Because breast cancer screening in the
Netherlands was implemented more than 25 years ago
(1989), there was no suitable control group or other reliable
estimate of the underlying breast cancer incidence available.
We here describe three methods for estimating test sen-
sitivity of mammography and mean sojourn time based on
modeling routine screening outcome data.
Method 1: based on maximum likelihood estimation
Test sensitivity, mean sojourn time, and underlying inci-
dence were estimated based on empirical screening data.
To determine the test sensitivity of mammography we cal-
culated the ratio of the number of screen-detected cancers
to the number of interval cancers diagnosed in the first
year after screening, plus all screen-detected cancers. The
assumption was made that interval cancers detected in the
first year after screening were missed cancers from the pre-
vious screen.20 Let k1 be the underlying incidence of pre-
clinical disease, k2 be the rate of disease progression from
preclinical to clinical phase, and S the screening test sen-
sitivity (of mammography). Let t be the interval between
screens in years. At first screen, the expected proportion of
persons found to have cancer would be
P ¼ k1S
k2
At incident screens, the expected proportion is21
I ¼ S
Z t
0
k1e
k1Sek2 tsð Þdsþ 1 sð Þek2t
Z t
0
k1e
k1Sek2 tsð Þds
 
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The first term within the brackets is the probability of
cancers newly arising in the preclinical phase since the last
screen and not progressing to a clinical disease before the
next screen. The second term is the probability of preclinical
cancers missed at the previous screen which have not pro-
gressed to the clinical phase within the screening interval.
There are two simplifying approximations here. The first is
that the first term of the formula applies if the previous screen
was also a subsequent (not a first) screen. Literature has
shown that interval cancer rates after a subsequent screen
are similar to interval cancer rates after a first screen.22
Applying this universally, regardless of the status of the pre-
vious screen, is therefore arguably a reasonable approxima-
tion. The second term is the absence of terms for cancers
missed at screens before the last screen. Here, we assume
that if a cancer ismissed at a screen, it will progress to a clinical
disease in the subsequent interval, be detected at the subse-
quent screen, or progress to a clinical disease in the interval
following the subsequent screen. This is an approximation;
however, we assume that the probability of missed cancer at
two successive screens is relatively small.23
The above formula with calculus then solves to
I ¼ S k1 e
k1t  ek2tð Þ 1þ 1 Sð Þek2t
 
k2  k1ð Þ
( )
The expected proportion of screen-negative subjects
having a clinical interval cancer before the next screen
(making the same approximations as for subsequent
screens) is
C ¼
Z t
0
k1e
k1S 1 ek2 tsð Þð Þdsþ I 1 Sð Þ 1 e
k2tð Þ
S
which solves to
C ¼ 1 k2e
k1t  k1ek2t
 
k2  k1ð Þ þ
I 1 Sð Þ 1 ek2tð Þ
S
Given these probabilities based on the three formulae
for P, I, and C, specific formulae for the log-likelihoods,
separately for first and subsequent screens, were specified.
After substituting the closed form estimates of S as above,
maximum likelihood estimation (MLE) on the total log-
likelihood was performed to obtain point estimates for k1
and k2. The point estimates of k1 and k2 were used to cal-
culate the expected values of P, I, and C. The 95% confi-
dence intervals around these expected values were
approximated and calculated by the following formula
Expected value e:g: Pð Þ1:96
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
P^ 1 P^ð Þ
total prevalent screens
s
Method 2: based on non-linear regression
If test sensitivity, calculated under the assumption that
interval cancers in the first year after screening are
missed cancers, is not adequately describing the real test
sensitivity of mammography, a more complex estimation
method is needed to estimate the three parameters at once.
Then, a three-state Markov model can be applied to depict
the progression process of breast cancer from the states of
free from breast cancer (state 0), preclinical disease (state
1), and clinical disease (state 2). Breast cancers detected at
screens were those in the preclinical detectable phase
(PCDP), and interval breast cancers were in the clinical
phase (CP).24,25 Let the underlying incidence of preclinical
disease and the rate of disease progression from preclinical
to clinical phase be denoted as above by k1 and k2, respec-
tively. The intensity matrix of the three-state model is thus
State 0 State 1 State 2
State 0
State 1
State 2
k1 k1 0
0 k2 k2
0 0 1
2
4
3
5
and the corresponding transition probability matrix for
interval between screens in years t
State 0 State 1 State 2
State 0
P tð Þ ¼ State 1
State 2
P00 tð Þ P01 tð Þ P02 tð Þ
0 P11 tð Þ P12 tð Þ
0 0 1
2
4
3
5
With the following definitions
P00 tð Þ ¼ ek1t
P01 tð Þ ¼ k1 e
k1t  ek2tð Þ
k2  k1ð Þ
P02 tð Þ ¼ 1 k2e
k1t
k2  k1 þ
k1ek2t
k2  k1
P11 tð Þ ¼ ek2t
P12 tð Þ ¼ 1 ek2t
The probabilities of observing preclinical cancers and sub-
jects free from breast cancer in the prevalent screening
round are thus
PCDP ¼ P01 vmð Þ
P00 vmð Þ þ P01 vmð Þ
 !
Free frombreast cancer ¼ P00 vmð Þ
P00 vmð Þ þ P01 vmð Þ
 ! (A)
where vm is age at prevalent screen. The probabilities
of observing clinical disease, preclinical disease, and
Aarts et al. 149
subjects free from breast cancer in the subsequent round
are thus
CP ¼ P01 tð Þ  k2
PCDP ¼ P01 tð Þ
Free frombreast cancer ¼ P00 tð Þ
(B)
where t is the interval between screens in years. For those
with preclinical disease or free of breast cancer in the sub-
sequent screen, t¼ 2 due to the biennial screening interval
in the Nijmegen breast cancer screening program. For clin-
ical cancers, t is the corresponding time between two
screens. Estimation of parameters was performed from
the above series of equations by letting the observed num-
bers equal the expected plus an error term for each mode
of detection using non-linear regression (NLR).24,25 For
the estimation of test sensitivity, the probabilities in for-
mula (A) and (B) were extended as follows
PCDP ¼ P01 vmð Þ
P00 vmð Þ þ P01 vmð Þ
 !
 S
Free frombreast cancer ¼ P00 vmð Þ
P00 vmð Þ þ P01 vmð Þ
 !
þ P01ðvmÞ
P00 vmð Þ þ P01ðvmÞ
 !
 1 Sð Þ
(C)
and
CP ¼ P01 tð Þ  k2 þ F0
n0
 1 S
S
 P11 tð Þ  k2
PCDP ¼ P01 tð Þ þ F0
n0
 1 S
S
 P11 tð Þ
Free from breast cancer ¼ P00 tð Þ þ 1 Sð Þ  P01 tð Þ
(D)
where F0 represents the total number of breast cancers
detected in the previous screen round and n0 represents the
number of attendees at previous screens.25 Considering the
model taking into account the heterogeneity in transition
rates, a regression model was adopted as follows
k1 ¼ k10 exp b1Xð Þ
k2 ¼ k20 exp b2Xð Þ
where X is a vector of dummy variables corresponding to
each period with the effect on underlying breast cancer
incidence rate and rate of progression through regression
coefficients b1 and b2, respectively, and k10 and k20 repre-
sent the baseline transition rates. The heterogeneity in sen-
sitivity (S) of each period was modeled using a
logistic form
S ¼ exp rXð Þ
1þ exp rXð Þ
The parameters were estimated by NLR, with the
expected numbers of cancers at first and subsequent
screens, and numbers of interval cancers based on the
above formulae as the regression predictor and the
observed numbers as the dependent variable.24
Method 3: based on Markov Chain Monte
Carlo simulation
We also applied Markov Chain Monte Carlo simulation
(MCMC) to estimate the parameters from the model
described above. The same formulae for probabilities
and expectations were used, but the parameters were
assigned vague prior distributions and estimated in a
Bayesian framework using MCMC.26 A Gibbs sampler
was used to derive samples of a stationary posterior dis-
tribution by which inferences on parameters were drawn.
A thinning interval of 3 with a burn-in interval of 10,000
and a total of 15,000 iterations were used, which yields a
total of 5000 updated posterior samples.
Results
The numbers of invited, screened, and referred women
over the four periods, as well as the numbers of screen-
detected and interval cancers, are presented in Table 1.
The attendance rate steadily increased over the four peri-
ods. The referral rate was stable in periods 1 and 2, but
increased during the last two periods, to 29 per 1000
women screened. The first rise in the referral rate coincided
with the optimization study and the recommendation to
increase referral.17 The second rise was seen after the intro-
duction of digital mammography. With digital mammog-
raphy (period 4), the screen-detected cancer rate increased
from 5 to almost 7 tumours per 1000 women screened.19,27
The number of screen-detected ductal carcinomas in situ
was also higher, however, the interval cancer rate
remained stable over the four periods.
Table 2 shows the estimates for test sensitivity, the
underlying breast cancer incidence, and mean sojourn
time over the four periods calculated by each of the
three methods (MLE, NLR, MCMC). The estimated
underlying breast cancer incidence has risen with approx-
imately 1 case per 1000 women per year in the final period
compared with the first for all methods. The calculated test
sensitivity of mammography using MLE was around 90%.
In contrast, the estimated test sensitivity using NLR and
MCMC was higher in period 4 (86% and 79%, respective-
ly) compared with the previous periods. The estimates of
mean sojourn time remained fairly stable over the first
three periods, whereas the point estimates of all methods
showed a small increase in period 4 compared with period
3 (MLE: 2.4 vs. 3.3, NLR: 3.6 vs. 4.4, MCMC: 4.3 vs. 4.6).
The mean sojourn time estimated based on MLE was three
years, while the estimates of NLR and MCMC were closer
to four years.
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Discussion
Our analysis over 40 years of breast cancer screening in
Nijmegen showed a trend towards higher test sensitivity
and longer mean sojourn time after the introduction of
digital mammography. The three methods used for obtain-
ing estimates of mammography test sensitivity and mean
sojourn time gave comparable results. However, the more
sophisticated methods, NLR and MCMC, which also esti-
mated test sensitivity from empirical screening data,
showed more realistic estimates.
The three methods applied in this study have been used
previously to estimate test sensitivity and mean sojourn
time, but have never been used to investigate these param-
eters over time as well as been directly compared with one
another before. Our estimates of mean sojourn time during
the period of analogue mammography (period 1–3) are
comparable with previous results.24,25 In contrast, the
results of period 4 are difficult to compare with what is
known, because to our knowledge there are no other
estimates of mean sojourn time based on digital mammog-
raphy. The slight increase in test sensitivity after the intro-
duction of digital mammography has been found
previously.19,27,28
A major strength of our study is that we were able to
investigate the consequences of changes in the screening
program on important parameters for the screening inter-
val over a 40-year follow-up period in a well-documented
screening program. As the Nijmegen screening program
has been running for decades, there were no women who
were not invited for screening or reliable estimate of the
underlying breast cancer incidence available. Therefore,
the underlying breast cancer incidence also needed to be
estimated. The estimated underlying breast cancer inci-
dence showed an upwards trend over the four periods.
A similar trend in the breast cancer incidence was seen
in women aged 45–49 in the Netherlands (unscreened pop-
ulation).29 This can be explained by opportunistic screen-
ing and an increase in breast cancer risk factors.
Table 1. Number of invited, screened, and referred women (aged 50–69) and number of screen-detected and interval-detected cancers for
all screens and first and subsequent screens separately in the Nijmegen Breast Cancer Screening Program in the period 1975–2012.
Period 1
1975–1988
Period 2
1989–2000
Period 3
2001–2006
Period 4
2007–2012
All screens
Invited 99,702 85,320 46,816 51,767
Screened 65,404 59,208 35,958 40,107
Attendance rate (%) 66 69 77 78
Referred 545 493 504 1168
Referral rate (per 1000 women screened) 8.3 8.3 14.0 29.1
Screen-detected cancera 260 (40) 263 (35) 175 (24) 263 (60)
Screen-detected rate (per 1000 women screened) 4.0 4.4 4.9 6.6
Interval cancer 130 121 82 84
Interval cancer rate (per 1000 women screened) 2.0 2.0 2.3 2.1
Interval cancer year 1 38 38 20 30
Interval cancer year 2 92 83 62 54
First screens
Screened 12,317 3,007 4,163 4,907
Attendance rate (%) 96.4 90.7 96.9 88.6
Referred 182 50 100 306
Referral rate (per 1000 women screened) 14.8 16.6 24.0 62.4
Screen-detected cancer 69 23 20 49
Screen-detected rate (per 1000 women screened) 5.6 7.6 4.8 10.0
Interval cancer 18 7 11 13
Interval cancer year 1 3 3 3 5
Interval cancer year 2 15 4 8 8
Subsequent screens
Screened 53,087 56,201 31,795 35,200
Attendance rate (%) 62.6 68.5 74.8 76.1
Referred 363 443 404 862
Referral rate (per 1000 women screened) 6.8 7.9 12.7 24.5
Screen-detected cancer 191 240 155 214
Screen-detected rate (per 1000 women screened) 3.6 4.3 4.9 6.1
Interval cancer 112 114 71 71
Interval cancer year 1 35 35 17 25
Interval cancer year 2 77 79 54 46
aIn parentheses, the number of ductal carcinoma in situ (DCIS) out of the total number of cancers.
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Furthermore, the stable interval cancer rates and higher
screen detection rates support a real increase in the inci-
dence, and not an increase in overdiagnosis. We also found
that the results of the three methods correlated well, which
may suggest that the estimates are accurate, also in com-
parison with previously published results for screening
with analogue mammography.24,30
Another strength is that our approach can easily be
applied to other (breast) cancer screening programs to
investigate the impact of changes in a screening program
on test sensitivity and sojourn time. The MLE method,
with a very simple closed form approximation for sensitiv-
ity, gave rather high estimates for sensitivity in the early
periods, but is fairly easy to use. Moreover, this method is
more constrained than the other two methods and argu-
ably gives confidence intervals that are too small, not
reflecting the entire uncertainty in the data. It may be
that the approximations used in this method were less
accurate than those in the more sophisticated methods
(NLR, MCMC). NLR assumes a Poisson distribution of
observed total numbers with their expectations, which
leads to very wide confidence intervals. MCMC takes
account of the conditionalities of these distributions on
the distributions of related variables, and could, therefore,
be argued to model more closely the interrelationships in
the data and the model parameters. Thus, MCMC has
arguably the most realistic confidence interval estimates.
As there is no gold standard for estimating mean sojourn
time, it is difficult to judge which of these three estimation
methods has the most reliable outcome. Furthermore, we
chose methods that can be applied to routinely collected
screening data instead of more complex data, such as
tumour size for calculating tumour volume/dou-
bling times.
An important limitation is the size of our dataset, as we
use data from a breast cancer screening program in a
single city in the Netherlands. Because of the limited
number of cancers detected and wide confidence intervals,
our results need to be interpreted with caution.
Nonetheless, all three methods, especially NLR and
MCMC, gave the impression that mean sojourn time
was longer after the introduction of digital mammogra-
phy. The point estimate of mean sojourn time is almost
1.5 years longer than when the screening program started
(NLR: 3.1 vs. 4.4 year, MCMC: 3.4 vs. 4.6 year). This may
be seen as the first piece of evidence towards considering a
longer screening interval. To be more certain about our
findings, validation of the results in a larger dataset would
be the next step. Furthermore, as not all breast cancers
have a mammographically detectable preclinical phase,
we can estimate the mean sojourn time only as an average
for the breast cancers that can be detected by mammogra-
phy and those that cannot. Moreover, it is likely that the
prognosis of the cancer in these two groups is different,
which may also have affected the estimates of mean
sojourn time.31 The potential introduction of new or addi-
tional screening modalities, such as digital breastT
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tomosynthesis, automated breast ultrasound, and breast
MRI, will probably make it possible to estimate the
mean sojourn time for a larger proportion of all breast
cancers. Future research should also include estimating
test sensitivity and mean sojourn time for subgroups of
women at varying levels of breast cancer risk. This could
underpin the length of the screening interval for subgroups
of women in the move towards a risk-based breast cancer
screening program, rather than the one-size-fits-all
approach based on age alone.
Conclusion
This study shows that test sensitivity and mean sojourn
time, while taking the underlying breast cancer incidence
rate into account, can be investigated based on routinely
available screening data, with more complex methods pro-
viding the most realistic outcomes.
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